Companies /Healthcare

AMGEN Inc

NASDAQ: AMGN Drug Manufacturers - General
$468.11
▲ $2.88 (+0.62%) today
Markets closed · 9:12pm ET

24/7 Wall St. View

Price Prediction $523.92 +11.9% Our analysts’ 12-month view: target, optimistic case, and floor. AMGN price prediction → Earnings Beat +11.5% EPS vs. the estimate, revenue, and how the market reacted. AMGN earnings history →

AMGN at a Glance

Valuation
Market cap
$251.6B
P/E ratio
27.0
Dividend yield
2.14%
Profitability
Revenue (TTM)
$38.9B
Profit margin
24.1%
EPS (TTM)
$17.25
Price
52-week range
$306 – $484
24/7 target
$523.92
Street target
$429.74
Earnings
Next report
Feb 1, 2027
Q3 2026 EPS
$6.45
vs. $5.78 est.
+11.5%

Headquartered in Thousand Oaks, CA Fiscal year ends December NASDAQ: AMGN amgen.com

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and sells medicines in general medicine, rare disease, inflammation and oncology, and is building a position in obesity and obesity-related conditions. Key growth products include:
- Repatha (cholesterol lowering) and EVENITY (osteoporosis)
- Rare disease therapies acquired with Horizon and ChemoCentryx: TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS
- TEZSPIRE for severe asthma, co-developed with AstraZeneca
- Oncology medicines BLINCYTO, IMDELLTRA, Vectibix, KYPROLIS, LUMAKRAS and Nplate

Amgen also sells biosimilars, including AMJEVITA, PAVBLU, WEZLANA and MVASI, and established products Aranesp, Neulasta and Parsabiv. Older franchises are under pressure: Prolia and XGEVA from denosumab biosimilars, and Enbrel from IRA Medicare Part D price setting. Most product sales are generated in the U.S., with the rest from international markets. The late-stage pipeline includes MariTide (monthly or less-frequent GLP-1/GIPR antibody-peptide conjugate for obesity), olpasiran (Lp(a) siRNA), xaluritamig (prostate cancer), dazodalibep (Sjögren's disease) and several biosimilars of major oncology and immunology biologics. Amgen is a component of the Dow Jones Industrial Average and the Nasdaq-100. Updated

Latest Activity

Halftime Report
PodcastHalftime ReportScott Wapner · 43 min

AI Relief Rally, Nvidia Governance and CoreWeave Earnings

  • Baird's Tristan Guerra calls for Nvidia's CEO to step down and cuts the target from $500 to $200 on China export governance
  • CoreWeave's beat and the CEO scrapping his stock sale plan triggered a 25% rally and broad AI relief
  • Panel splits on whether semis bottomed: Broadcom down 33%, AMD down 22%, chip equipment names off 30-50%
  • Goldman floats a third hike into March 2027 as Lebenthal argues for 50bp in December; retail holds up on eight straight XRT weekly gains

The bull case for chips now rests on multiples: Amoroso notes semiconductor PEs sit at their lowest since 2022, while Terranova says the bottom is in. On the consumer side the panel leans toward auto-parts repair names over discretionary retail, with record credit card debt the counterweight.

Read more
AMGNAmgen
New 52-week high$478.48+2.7% vs prior high · 2026-10-30

Amgen just cleared its October 30 record with a $478.48 close, 2.68% above the prior peak and the fourth new high in barely a week. Anyone waiting for a pullback in this biotech hasn't gotten one.

Read more
AMGNAmgen
Q3 2026
EPS
$6.45
est $5.78+11.6%
Revenue
$10.37B
est $10.07B+3.0%

Biosimilars cut Prolia 45% and XGEVA 47%, yet Amgen still came in 11.55% above expectations. Management now guides full-year non-GAAP EPS of $22.90 to $23.70, the number to judge the denosumab cliff against.

Quarterly EPS — reported vs estimate
Read more
New insider tie · Form 3David W Gibbs
Now director at AMGEN INC

The retiring Yum! Brands CEO brings three decades of global consumer scale and pricing discipline to a $242 billion drugmaker that is leaning hard on commercial execution behind obesity and oncology bets. Board additions rarely move a stock, but they signal where management wants outside pressure applied.

Read more
AMGNAmgen
New 52-week high$447.28+0.7% vs prior high · 2026-09-03

Amgen closed at $447.28, a new 52-week high, roughly 55% above last October's $288 level. The $241.8 billion name now sits at the top of its range.

Read more

AMGN Coverage

Load More

Frequently Asked Questions

What does Amgen do?

Amgen is a biotechnology company that discovers, develops, manufactures and sells medicines in general medicine, rare disease, inflammation and oncology, and is building a position in obesity and obesity-related conditions.

What is the AMGN stock price target?

24/7 Wall St.'s 12-month price target for AMGN is $523.92, rated Buy. The Wall Street consensus target is $429.74. AMGN price prediction →